Cytokinetics seeing ‘strong interest’ from strategic suitors, Dealreporter says

Cytokinetics (CYTK) is seeing “strong interest” from Novartis (NVS) and AstraZeneca (AZN) as the heart-disease focused drugmaker weighs options after receiving takeover interest, said Dealreporter, citing three sources familiar with the matter. In addition to Novartis and AstraZeneca, other potential strategic buyers have also been engaging, but the strategic suitors are in “wait-and-see” mode ahead of the biopharmaceutical company announcing late-stage data for its heart disease drug aficatmten “any time this month,” the report stated, contacts tell The Fly. Bloomberg previously reported on October 31 that Cytokinetics was evaluating options amid takeover interest.